Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Polynovo (ASX:PNV) soars 25% on record US sales

The share price of medical device company Polynovo Ltd (ASX: PNV), which develops burns and surgical wound treatments, has caught fire today after announcing a record month for sales in the United States (US).

The business also provided an unaudited update for the first-half ending 31 December.

Subsequently, the Polynovo share price is up 25% to $1.80.

PNV share price

Source: Rask Media PNV 2-year share price
Source: Rask Media PNV 2-year share price

Record December buoys investors

Polynovo achieved a record sales month for its key US market, recording AU$3.4 million (US$2.4 million) in December.

The result was a 76% improvement compared to the same month in 2020 and is the first time the company has exceeded US$2.0 million monthly sales.

Justifying the recent departure of its CEO Paul Brennan, the company recorded AU$8.1 million (US$5.9 million) in second-quarter sales, a 105% improvement on the prior year.

Additionally, Polynovo recorded AU$14.2 million (US$10.4 million) US sales in the first half.

Mr Brennan resigned from his role in November over management disagreements.

“…in more recent times there have been increasing differences with the Board in relation to Paul’s interaction with the company’s senior management team and his management style.

To continue the positive second-quarter momentum, the business will add a further 10 sales reps.

Commenting on the result, Senior VP Sales & Marketing Americas, Ed Graubart said:

“We have recruited top talent and they in turn are transitioning new accounts at a record pace. We have also filled some critical internal positions that allow for a more efficient and effective organisation. The team are buoyed by the strong results and opportunities.”

Rest of the world weighs on results

Total group revenue for the first half (ex Barda) was AU$16.3 million, a 45% year-on-year improvement.

Including Barda revenue, Polynovo achieved AU$18.0 million in revenue, a 43% improvement.

The unaudited result implies rest of the world revenue was slightly down compared to the prior year:

“The major focus markets outside the US have been patchy, but initiatives are being undertaken to improve the effectiveness of our in-market programs, our direct sales force and distributor networks”

My take

December’s monthly sales infer an annualised US sales base of $28.8 million.

For a business with a market capitalisation greater than $1 billion, that’s a hefty multiple to be paying.

I really like the company, but today’s valuation isn’t compelling for me just yet.

Particularly after today’s share price jump.

If you’re looking to learn how to do your own ASX company valuations, take our free share valuation course, which takes you through 6 common share valuation techniques, step by step.

Or try our Beginner Shares Course if you’re just starting out. Both are free.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Lachlan does not have a financial or commercial interest in any of the companies or funds mentioned.
Skip to content